With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Business Wire15h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
BMJ39m
FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare
Despite major advances in artificial intelligence (AI) research for healthcare, the deployment and adoption of AI technologies remain limited in clinical practice. This paper describes the FUTURE-AI ...
ophthalmologyadvisor21h
Micronutrient Deficiencies Seen in More Than 45 Percent With Type 2 Diabetes
More than 45% of patients with type 2 diabetes (T2D) have micronutrient deficiencies, with the most prevalent deficiency ...